Ontology highlight
ABSTRACT: Objective
To evaluate the rate of over-diagnosis of breast cancer 15 years after the end of the Malmö mammographic screening trial.Design
Follow-up study.Setting
Malmö, Sweden.Subjects
42 283 women aged 45-69 years at randomisation.Interventions
Screening for breast cancer with mammography or not (controls). Screening was offered at the end of the randomisation design to both groups aged 45-54 at randomisation but not to groups aged 55-69 at randomisation.Main outcome measures
Rate of over-diagnosis of breast cancer (in situ and invasive), calculated as incidence in the invited and control groups, during period of randomised design (period 1), during period after randomised design ended (period 2), and at end of follow-up.Results
In women aged 55-69 years at randomisation the relative rates of over-diagnosis of breast cancer (95% confidence intervals) were 1.32 (1.14 to 1.53) for period 1, 0.92 (0.79 to 1.06) for period 2, and 1.10 (0.99 to 1.22) at the end of follow-up.Conclusion
Conclusions on over-diagnosis of breast cancer in the Malmö mammographic screening trial can be drawn mainly for women aged 55-69 years at randomisation whose control groups were never screened. Fifteen years after the trial ended the rate of over-diagnosis of breast cancer was 10% in this age group.
SUBMITTER: Zackrisson S
PROVIDER: S-EPMC1410836 | biostudies-literature | 2006 Mar
REPOSITORIES: biostudies-literature
Zackrisson Sophia S Andersson Ingvar I Janzon Lars L Manjer Jonas J Garne Jens Peter JP
BMJ (Clinical research ed.) 20060303 7543
<h4>Objective</h4>To evaluate the rate of over-diagnosis of breast cancer 15 years after the end of the Malmö mammographic screening trial.<h4>Design</h4>Follow-up study.<h4>Setting</h4>Malmö, Sweden.<h4>Subjects</h4>42 283 women aged 45-69 years at randomisation.<h4>Interventions</h4>Screening for breast cancer with mammography or not (controls). Screening was offered at the end of the randomisation design to both groups aged 45-54 at randomisation but not to groups aged 55-69 at randomisation. ...[more]